Novartis CEO-Designate Set To Bring More Automation To Drug Discovery

Vasant Narasimhan, who is replacing Joseph Jimenez as Novartis' CEO next year, is an advocate of automation and artificial intelligence in future drug discovery.

Relay
Novartis CEO Joe Jimenez Will Hand Over To Vas Narasimhan On Feb 1, 2018 • Source: Shutterstock

With Novartis AG's root-to-branch revamp a reality, its American CEO Joseph Jimenez is passing the leadership baton to the Swiss group's chief medical officer Vasant Narasimhan – another American who has been increasingly at the center of its drug development and commercialization strategy and who is a big proponent of automation and artificial intelligence in future discovery.

News of Jimenez's departure - effective Feb. 1, 2018 - came as a surprise to the industry, and comes after...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Executives On The Move

More from Leadership